|
Oct 1
|
Satellos to Present Data on SAT-3247 Pilot Study at World Muscle Society Meeting
|
|
Oct 1
|
Satellos Demonstrates Treatment of DMD Canines with SAT-3247 Improved Measures of Strength to Near Normal Levels
|
|
Jan 16
|
Satellos Receives Conditional Approval to Graduate to the Toronto Stock Exchange
|
|
Nov 14
|
Satellos Discloses Drug Target and Provides Development Update on Duchenne Muscular Dystrophy Program
|
|
Sep 7
|
Satellos Bioscience Enters Into an Agreement with ICP Securities Inc. to Provide Market Making Services
|
|
Sep 5
|
Satellos Expands Leadership Team with New CFO Appointment
|
|
Jun 30
|
Satellos Bioscience Announces Results from Its Annual General Meeting of Shareholders and Adoption of Amendments to Stock Option Plan
|
|
May 21
|
Executive Director of Satellos Bioscience William Jarosz Buys 263% More Shares \
|